Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas W Mapel

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|December 3, 2011
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claimsDouglas W Mapel, Anand A Dalal, Christopher M Blanchette, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 12, 2011
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseAnand A Dalal, Melissa H Roberts, Hans V Petersen, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 8, 2015
Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severityDouglas W Mapel, Anand A Dalal, Phaedra T Johnson, et al.
COPD|May 29, 2007
Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators aloneDouglas W Mapel, Leila S Nelson, Eva Lydick, et al.
BMC Pulmonary Medicine|May 1, 2016
A retrospective analysis to identify predictors of COPD-related rehospitalizationMelissa H Roberts, Emmanuelle Clerisme-Beaty, Chris M Kozma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 16, 2008
The direct medical costs of undiagnosed chronic obstructive pulmonary diseaseDouglas W Mapel, Scott B Robinson, Homa B Dastani, et al.
The American Journal of Managed Care|July 22, 2010
Can outpatient pharmacy data identify persons with undiagnosed COPD?Douglas W Mapel, Hans Petersen, Melissa H Roberts, et al.
Journal of Managed Care Pharmacy : JMCP|August 24, 2006
An algorithm for the identification of undiagnosed COPD cases using administrative claims dataDouglas W Mapel, Floyd J Frost, Judith S Hurley, et al.
Respiratory Medicine|October 4, 2005
Survival of COPD patients using inhaled corticosteroids and long-acting beta agonistsDouglas W Mapel, Judith S Hurley, Douglas Roblin, et al.
Drugs - Real World Outcomes|October 18, 2016
Severe COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis MethodsMelissa H Roberts, Douglas W Mapel, Matthew E Borrego, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
International Journal of Chronic Obstructive Pulmonary Disease|December 3, 2011
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claimsDouglas W Mapel, Anand A Dalal, Christopher M Blanchette, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 12, 2011
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseAnand A Dalal, Melissa H Roberts, Hans V Petersen, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 8, 2015
Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severityDouglas W Mapel, Anand A Dalal, Phaedra T Johnson, et al.
COPD|May 29, 2007
Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators aloneDouglas W Mapel, Leila S Nelson, Eva Lydick, et al.
BMC Pulmonary Medicine|May 1, 2016
A retrospective analysis to identify predictors of COPD-related rehospitalizationMelissa H Roberts, Emmanuelle Clerisme-Beaty, Chris M Kozma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 16, 2008
The direct medical costs of undiagnosed chronic obstructive pulmonary diseaseDouglas W Mapel, Scott B Robinson, Homa B Dastani, et al.
The American Journal of Managed Care|July 22, 2010
Can outpatient pharmacy data identify persons with undiagnosed COPD?Douglas W Mapel, Hans Petersen, Melissa H Roberts, et al.
Journal of Managed Care Pharmacy : JMCP|August 24, 2006
An algorithm for the identification of undiagnosed COPD cases using administrative claims dataDouglas W Mapel, Floyd J Frost, Judith S Hurley, et al.
Respiratory Medicine|October 4, 2005
Survival of COPD patients using inhaled corticosteroids and long-acting beta agonistsDouglas W Mapel, Judith S Hurley, Douglas Roblin, et al.
Drugs - Real World Outcomes|October 18, 2016
Severe COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis MethodsMelissa H Roberts, Douglas W Mapel, Matthew E Borrego, et al.
Pageof 6